Target intelligence / Profile preview

Fas receptor (CD95, TNFRSF6) and Fas ligand (CD95L, Apo-1L, tumor necrosis factor ligand superfamily member 6) (Fas (for the receptor), FasL (for the ligand))

Target
Fas (for the receptor), FasL (for the ligand)
Molecular classification
Receptor, Death receptor, Type I transmembrane protein, Member of TNF receptor superfamily, Ligand, Type II transmembrane protein, Member of TNF ligand superfamily
01

Overview

The Fas receptor (CD95, TNFRSF6) is a cell-surface death receptor in the tumor necrosis factor receptor superfamily, containing a death domain essential for mediating apoptosis through recruitment of FADD and activation of caspases when engaged by its natural ligand, Fas ligand (FasL/ CD95L). Fas ligand is a type-II transmembrane protein in the tumor necrosis factor ligand superfamily. Its binding to Fas receptor catalyzes formation of the death-inducing signaling complex (DISC), leading to caspase-8 and downstream effector caspase-3 activation, cell death, and immune privilege. Fas/FasL interactions tightly regulate T-cell lifespan, immune homeostasis, and the elimination of autoreactive lymphocytes. Dysregulation is linked to autoimmune lymphoproliferative syndromes, cancer escape, and transplantation rejection. Both molecules exist in membrane-bound and soluble forms, each with distinct biological activities and regulatory roles.

Other names
CD95APO-1TNFRSF6FasLCD95LApo-1LFASLG
02

Mechanism of action

Induction or inhibition of apoptosis by modulating receptor-ligand interaction (e.g. agonists trigger apoptosis; inhibitors block immune cell death). Modulation of immune cell activation and survival.

03

Biological functions

Apoptosis inductionImmune response regulationCell deathSignal transduction (including activation of caspases, NF-κB, MAPK)Termination of immune responses
04

Disease associations

Cancer (tumor immune evasion, lymphomas)Autoimmune disease (autoimmune lymphoproliferative syndrome, ALPS)InflammationTransplantation tolerance/rejectionInfection
05

Safety considerations

Exaggerated Fas signaling causes loss of immune cells, tissue damage, and lethal fulminant hepatitisBlockade impairs immune regulation, fostering autoimmune proliferationSystemic activation leads to excessive apoptosis and inflammatory cytokine release ("cytokine storm")Tumor cells may evade immune detection by overexpressing FasL, killing infiltrating lymphocytes
06

Interacting drugs

Agonistic anti-Fas antibodies

2 more in the full profile.

07

Biomarkers

Fas expression levels (tissue or plasma)FasL expression levels (tissue or plasma)

Beyond the preview

Go deeper on Fas receptor (CD95, TNFRSF6) and Fas ligand (CD95L, Apo-1L, tumor necrosis factor ligand superfamily member 6) (Fas (for the receptor), FasL (for the ligand)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fas receptor (CD95, TNFRSF6) and Fas ligand (CD95L, Apo-1L, tumor necrosis factor ligand superfamily member 6) (Fas (for the receptor), FasL (for the ligand)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call